The deal will begin with a tender offer. Aytu will tender shares representing at least a majority of its outstanding stock, after which Rosemont would acquire any remaining shares through a merger. Aytu’s board has approved the transaction.
Aytu develops medicines for complex central nervous system diseases. The acquisition is intended to strengthen Rosemont’s position in the specialty pharmaceutical market. Rosemont is backed by private-equity firm Inflexion.




Comments (0)
No comments yet. Be the first!